Inhibrx Biosciences (INBX) Operating Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Operating Expenses data on file, last reported at $30.9 million in Q4 2025.

• Operating Expenses for Q4 2025 came in at $30.9 million, down 38.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $136.3 million (down 58.89% YoY), and the FY2025 annual result was $136.3 million, down 58.89% from the prior year.
• Operating Expenses eased to $30.9 million in Q4 2025 per INBX's latest filing, from $33.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $161.0 million in Q2 2024 and troughed at $28.7 million in Q2 2025.
• A 3-year average of $58.7 million and a median of $45.9 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses soared 289.18% in 2024, then tumbled 82.18% in 2025.
• A 3-year view of Operating Expenses shows it stood at $89.9 million in 2023, then sank by 44.37% to $50.0 million in 2024, then sank by 38.19% to $30.9 million in 2025.
• Business Quant data shows INBX's Operating Expenses at $30.9 million in Q4 2025, $33.8 million in Q3 2025, and $28.7 million in Q2 2025.